Health care startups in Schlieren, Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Memo Therapeutics | Schlieren | Series C | $22.0M | 2024-05-07 |
| NovaGo Therapeutics | Schlieren | Series B | $29.7M | 2026-08-31 |
| Hemotune | Schlieren | Series B | $15.6M | 2024-03-25 |
| CDR-Life AG | Schlieren | Series A | $76.0M | 2022-04-13 |
| ImmunOs Therapeutics | Schlieren | Series C | $11.0M | 2024-09-17 |
| Anjarium Biosciences | Schlieren | Series A | $60.4M | 2021-09-15 |
| Malcisbo | Schlieren | Pre-seed | $95K | 2010-07-07 |
| Roche Glycart | Schlieren | Series A | $13.6M | 2003-11-26 |
8 rows of the CSV in 5 of its 18 columns.
- The 22 health care startups in Schlieren, Switzerland have raised $247.6M in total.
- 4 of them closed their most recent round in the last 12 months, $30.7M combined.
- The largest of those rounds is NovaGo Therapeutics' $29.7M Series B, dated August 2026.
- The most recent is Vale Biolabs' $183K seed round on 9 November 2026.
- Venture Kick is an investor in 4 of them, more than any other fund.
- Biotech is the most common other sector, with 17 companies (77%).
- 18% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 1 to 10 employees (59% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
12 of 22| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| ImmunOs Therapeutics | ImmunOs Therapeutics is a clinical-stage biotechnology company. | Biotech | Series C | $11.0M | 2024-09-17 | Lightspeed Venture Partners, Innosuisse, Mission BioCapital +1 | 11 to 50 | 2014 | |
| Memo Therapeutics | Memo Therapeutics conducts biotechnology research in antibody discovery and immune repertoire analysis. | Biotech | Series C | $22.0M | 2024-05-07 | $108.8M | Verve Ventures, Kurma Partners, Pureos Bioventures +1 | 11 to 50 | 2012 |
| Hemotune | Hemotune develops a therapeutic blood purification platform for treating health conditions. | Biotech | Series B | $15.6M | 2024-03-25 | Venture Kick, Innosuisse, Gebert Rüf Stiftung | 11 to 50 | 2016 | |
| CDR-Life AG | CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. | Biotech | Series A | $76.0M | 2022-04-13 | $76.0M | RA Capital Management, Omega Funds, Jeito Capital | 51 to 100 | 2017 |
| Anjarium Biosciences | Anjarium Biosciences develops non-viral gene therapies to treat genetic diseases. | Biotech | Series A | $60.4M | 2021-09-15 | Gimv, Omega Funds, Pfizer Venture Investments +2 | 1 to 10 | 2017 | |
| Inthera Bioscience | Inthera Bioscience develops inhibitors of intracellular protein interactions using a proprietary technology platform. | Biotech | Series A | $5.5M | 2018-06-26 | Microsoft Accelerator, Novo Holdings, M Ventures +2 | 11 to 50 | 2013 | |
| Covagen | Covagen develops protein-based therapeutics for inflammatory diseases and cancer. | Biotech | Series B | $66.1M | 2013-12-09 | Ventech, Novartis Venture Fund, Andera Partners +2 | 11 to 50 | 2007 | |
| Pearltec AG | Pearltec provides placement, positioning, and fixation solutions for patients in research imaging studies. | Health care | Series B | $2.0M | 2012-07-23 | Tugboat | 1 to 10 | 2008 | |
| Malcisbo | Malcisbo develops novel carbohydrate-based vaccines for human and animal health. | Biotech | Pre-seed | $95K | 2010-07-07 | $124K | Venture Kick | 1 to 10 | 2010 |
| ESBATech | ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. | Biotech | Series B | $22.0M | 2008-08-07 | Novartis Venture Fund, VI Partners, SV Health Investors +2 | 51 to 100 | 1998 | |
| Roche Glycart | Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. | Biotech | Series A | $13.6M | 2003-11-26 | $13.6M | Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 | 101 to 250 | 2000 |
Table 1. Health care startups in Schlieren, Switzerland: the 12 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 22.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
Table 2. Health care startups in Schlieren, Switzerland: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Venture Kick | Startup incubator | Schlieren, Switzerland | 4 | 18% | ||
| 2 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 14% | ||
| 3 | Pureos Bioventures | Venture capital firm | Küsnacht, Switzerland | 2 | 9% | 1 | NovaGo Therapeutics |
| 4 | Innosuisse | Government investment office | Berne, Switzerland | 2 | 9% | ||
| 5 | Omega Funds | Secondary purchaser | Boston, United States | 2 | 9% | ||
| 6 | Gimv | Private equity firm | Antwerp, Belgium | 2 | 9% | ||
| 7 | Ysios Capital | Venture capital firm | San Sebastian, Spain | 1 | 5% | ||
| 8 | Kurma Partners | Venture capital firm | Paris, France | 1 | 5% | ||
| 9 | Verve Ventures | Venture capital firm | Zug, Switzerland | 1 | 5% | ||
| 10 | Kinled Holding | Private equity firm | New York, United States | 1 | 5% | 1 | NovaGo Therapeutics |
| 11 | Gebert Rüf Stiftung | Entrepreneurship program | Basel, Switzerland | 1 | 5% | ||
| 12 | RA Capital Management | Startup incubator | Boston, United States | 1 | 5% | ||
| 13 | Jeito Capital | Private equity firm | Paris, France | 1 | 5% | ||
| 14 | Mission BioCapital | Venture capital firm | Cambridge, United States | 1 | 5% | ||
| 15 | Lightspeed Venture Partners | Venture capital firm | Menlo Park, United States | 1 | 5% |
Table 3. Health care startups in Schlieren, Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 17 | 77% | $247.4M |
| Software | 3 | 14% | $4K |
| Artificial intelligence | 1 | 5% | $4K |
Table 4. Health care startups in Schlieren, Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Pre-seed | 4 | 18% | $106K |
| Seed | 4 | 18% | $7.8M |
| Series A | 6 | 27% | $60.4M |
| Series B | 5 | 23% | $22.0M |
| Series C | 2 | 9% | $22.0M |
| Series D+ | 1 | 5% |
Table 5. Health care startups in Schlieren, Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 25% | $183K |
| August 2026 | 1 | 25% | $29.7M |
| February 2026 | 1 | 25% | $873K |
| January 2026 | 1 | 25% |
Table 6. Health care startups in Schlieren, Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 18% | $30.7M |
| 2025 | 1 | 5% | $7.8M |
| 2024 | 3 | 14% | $48.6M |
| 2022 | 2 | 9% | $76.0M |
| 2021 | 1 | 5% | $60.4M |
| 2019 | 1 | 5% |
Table 7. Health care startups in Schlieren, Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 14% |
| 2020 to 2022 | 1 | 5% |
| 2015 to 2019 | 6 | 27% |
| 2010 to 2014 | 7 | 32% |
| Before 2010 | 5 | 23% |
Table 8. Health care startups in Schlieren, Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 13 | 59% |
| 11 to 50 | 5 | 23% |
| 51 to 100 | 3 | 14% |
| 101 to 250 | 1 | 5% |
Table 9. Health care startups in Schlieren, Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its headquarters is in Schlieren, Switzerland. On 16 November 2026 that is 22 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 12 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 22 rows: 6 have no round amount, 0 no city and 8 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Schlieren, Switzerland are on the list?
- 22, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 22 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.